# 2026-08812: Circulating Tumor Cell Device Gets Safer FDA Classification

2026-08812, Medical Devices; Immunology and Microbiology Devices; Classification of the Circulating Tumor Cell Enrichment Device, is a Federal Register rule from Health and Human Services Department, Food and Drug Administration published 2026-05-06, effective 2026-05-06; PRIA reads it as touching household money (as of 2026-06-11).

- Canonical: https://policyrisk.com/federal-register/2026-08812
- As of: 2026-06-11
- Plain-text twin of the page above; the HTML and this file carry the same facts.

## Facts
- Document number: 2026-08812
- Title: Medical Devices; Immunology and Microbiology Devices; Classification of the Circulating Tumor Cell Enrichment Device
- Type: Rule
- Agencies: Health and Human Services Department; Food and Drug Administration
- Citation: 91 FR 24343
- Published: 2026-05-06
- Effective: 2026-05-06
- Comments close: not stated
- Significant: no
- Touches household money: yes
- Regulation identifier numbers: none
- Last updated: 2026-06-11

## In one line

Circulating Tumor Cell Device Gets Safer FDA Classification

## Summary

The FDA is officially classifying the circulating tumor cell enrichment device as a Class II device, meaning it has special safety rules but fewer hurdles than the strictest category. This change helps patients get access to innovative cancer-fighting tools faster and keeps the device safe and effective. The new rules take effect May 6, 2026, and could save time and money for makers and users of this device.

## Abstract

The Food and Drug Administration (FDA) is classifying the circulating tumor cell enrichment device into class II (special controls). The special controls that apply to the device type are identified in this order and will be part of the codified language for classification of the circulating tumor cell enrichment device. We are taking this action because we have determined that classifying the device into class II will provide a reasonable assurance of safety and effectiveness of the device. We believe this action will also enhance patients' access to beneficial innovative devices, in part by reducing regulatory burdens.

## Effects PRIA read

- Device Reclassified to Class II: benefit, medium. FDA has classified the circulating tumor cell enrichment device as Class II (special controls). This order is effective May 6, 2026 (and the classification was applicable May 24, 2022). FDA says this classification will provide reasonable assurance of safety and effectiveness and will enhance patie…
- Easier Path for Future Devices: benefit, high. FDA states that once this device type is classified into Class II via the De Novo process, it can serve as a predicate for future devices. That means other device sponsors may be able to use the less-burdensome 510(k) process to bring substantially equivalent devices to market instead of submitting…
- Manufacturers Must Meet Special Controls: cost, medium. Circulating tumor cell enrichment devices remain subject to premarket notification under section 510(k) and must meet the special controls codified at 21 CFR 866.6110. Manufacturers must provide specified labeling (including intended use, limitations, and troubleshooting) and design verification an…
- Labeling Limits Use; Not Diagnostic: benefit, low. The device's labeling must prominently state that the standalone device is intended only to enrich circulating tumor cells (CTCs) from peripheral blood of previously diagnosed cancer patients and is not intended for diagnostic, prognostic, or monitoring use. Labeling must also state that results do…

## Related documents

- [2026-20848](https://policyrisk.com/federal-register/2026-20848): Use of Salt Substitutes To Reduce the Sodium Content in Standardized Foods, 2026-10-13
- [2026-16296](https://policyrisk.com/federal-register/2026-16296): Substances Generally Recognized as Safe, 2026-08-11
- [2026-14073](https://policyrisk.com/federal-register/2026-14073): Drug Establishment Registration and Drug Listing Requirements for Establishments Engaged in Distributed Manufacturing and Certain Foreign E…, 2026-07-13
- [2026-13047](https://policyrisk.com/federal-register/2026-13047): Establishment Registration and Product Listing for Tobacco Products, 2026-06-29
- [2025-04978](https://policyrisk.com/federal-register/2025-04978): Nonprescription Drug Product With an Additional Condition for Nonprescription Use, 2025-03-25
- [2025-01840](https://policyrisk.com/federal-register/2025-01840): Nonprescription Drug Product With an Additional Condition for Nonprescription Use, 2025-01-27

## Sources
- [2026-08812 on federalregister.gov](https://www.federalregister.gov/documents/2026/05/06/2026-08812/medical-devices-immunology-and-microbiology-devices-classification-of-the-circulating-tumor-cell)
- [2026-08812 as published (PDF)](https://www.govinfo.gov/content/pkg/FR-2026-05-06/pdf/2026-08812.pdf)

## Related
- [Previous: 2026-08811, Medical Devices; Immunology and Microbiology Devices; Classification of the Dev…](https://policyrisk.com/federal-register/2026-08811)
- [Next: 2026-08813, Medical Devices; Ophthalmic Devices; Classification of the Corneal Storage Medi…](https://policyrisk.com/federal-register/2026-08813)
- [All Federal Register documents](https://policyrisk.com/federal-register)

Source: PRIA, https://policyrisk.com/federal-register/2026-08812 (as of 2026-06-11).
